U.S. Markets closed

Should You Buy Acorda Therapeutics Inc (ACOR) Now?

Jason Fuller

Acorda Therapeutics Inc (NASDAQ:ACOR), a pharmaceuticals, biotechnology and life sciences company based in United States, Check out our latest analysis for Acorda Therapeutics

Is ACOR still cheap?

Great news for investors – ACOR is still trading at a fairly cheap price. My valuation model shows that the stock’s value should be $32.5 but it is currently trading at $23.2 on the share market, meaning that there is still an opportunity to buy now. However, given that ACOR’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What kind of growth will ACOR generate?

NasdaqGS:ACOR Future Profit Sep 13th 17

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio.Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. However, with an extremely negative double-digit change in profit expected over the next couple of years, near-term growth is certainly not a driver of a buy decision. It seems like high uncertainty is on the cards for ACOR, at least in the near future.

What this means for you:

Are you a shareholder? Although ACOR is currently undervalued, the negative outlook does bring on some uncertainty, which equates to higher risk. Consider whether you want to increase your portfolio exposure to ACOR, or whether diversifying into another stock may be a better move for your total risk and return.

Are you a potential investor? If you’ve been keeping tabs on ACOR for some time, but hesitant on making the leap, I recommend you dig deeper into the stock. Given its current undervaluation, now is a great time to make a decision. But keep in mind the risks that come with negative growth prospects in the future.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Acorda Therapeutics. You can find everything you need to know about ACOR in the latest infographic research report. If you are no longer interested in Acorda Therapeutics, you can use our free platform to see my list of over 50 other stocks with a high growth potential.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.